QURE: uniQure NV
About
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Current Value
$5.761 Year Return
Current Value
$5.761 Year Return
Key Details
Market Cap
$283.68M
P/E Ratio
-1.17
1Y Stock Return
-13.52%
1Y Revenue Growth
-74.45%
Dividend Yield
0.00%
Price to Book
5.1
Strategies that include QURE
Stock's related to QURE
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KYMR | 37.89% | $2.77B | +125.95% | 0.00% |
| ARLO | 37.01% | $1.20B | +31.21% | 0.00% |
| SEI | 35.47% | $616.12M | +133.06% | 2.39% |
| CLPT | 32.57% | $302.60M | +84.68% | 0.00% |
| IMVT | 29.66% | $3.70B | -23.48% | 0.00% |
| EDIT | 28.94% | $204.72M | -75.49% | 0.00% |
| LNTH | 28.12% | $5.52B | +16.60% | 0.00% |
| VYGR | 27.22% | $287.88M | -21.46% | 0.00% |
| GPRO | 27.10% | $179.52M | -67.23% | 0.00% |
| HE | 27.02% | $1.82B | -17.47% | 0.00% |
| JMIA | 27.00% | $380.31M | +30.53% | 0.00% |
| RLMD | 26.75% | $89.92M | +1.36% | 0.00% |
| ERJ | 26.34% | $6.92B | +134.10% | 0.00% |
| RCKT | 25.96% | $1.20B | -39.83% | 0.00% |
| ARWR | 25.30% | $2.31B | -34.44% | 0.00% |
| TVTX | 25.28% | $1.51B | +207.79% | 0.00% |
| ABUS | 25.14% | $661.33M | +90.71% | 0.00% |
| IVZ | 24.98% | $7.76B | +25.60% | 4.72% |
| ESE | 24.95% | $3.77B | +40.05% | 0.22% |
| IOVA | 24.93% | $2.50B | +58.41% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| OR | 0.00% | $3.69B | +45.97% | 0.94% |
| AMPY | <0.01% | $260.89M | +7.01% | 0.00% |
| COP | <0.01% | $130.16B | -1.63% | 2.59% |
| NOG | 0.01% | $4.10B | +9.43% | 3.97% |
| EDSA | 0.01% | $7.11M | -21.79% | 0.00% |
| INFY | 0.02% | $90.23B | +24.60% | 2.66% |
| ZCMD | -0.02% | $2.80M | -88.67% | 0.00% |
| BWXT | -0.03% | $11.92B | +67.39% | 0.91% |
| AZPN | -0.04% | $15.62B | +34.34% | 0.00% |
| MODV | 0.04% | $222.68M | -59.06% | 0.00% |
| TBI | 0.05% | $199.52M | -50.80% | 0.00% |
| SEG | 0.05% | $319.72M | +12.41% | 0.00% |
| NTIC | 0.05% | $132.27M | +24.98% | 2.02% |
| SXC | 0.05% | $1.05B | +39.93% | 3.52% |
| CRWD | 0.06% | $86.61B | +69.05% | 0.00% |
| MUSA | -0.07% | $10.62B | +42.37% | 0.34% |
| PRG | 0.07% | $1.94B | +70.71% | 1.03% |
| DLR | -0.07% | $62.12B | +37.49% | 2.63% |
| SPOT | -0.08% | $90.80B | +159.59% | 0.00% |
| CTLP | -0.08% | $653.23M | +34.18% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HELE | -34.88% | $1.53B | -34.86% | 0.00% |
| LUMO | -19.60% | $37.45M | +41.97% | 0.00% |
| HUBS | -15.51% | $35.23B | +44.73% | 0.00% |
| BRBR | -15.48% | $9.47B | +50.71% | 0.00% |
| LZ | -14.51% | $1.30B | -33.57% | 0.00% |
| FRPT | -13.66% | $7.59B | +126.44% | 0.00% |
| MNOV | -13.08% | $93.19M | +2.15% | 0.00% |
| UONEK | -11.54% | $46.08M | -77.68% | 0.00% |
| UTZ | -10.72% | $1.37B | +26.87% | 1.41% |
| PGR | -10.59% | $149.10B | +57.29% | 0.45% |
| BP | -10.45% | $77.24B | -18.61% | 6.32% |
| CME | -9.92% | $82.76B | +9.21% | 1.98% |
| DT | -9.30% | $15.40B | -1.30% | 0.00% |
| CMG | -9.25% | $80.02B | +33.62% | 0.00% |
| CHEF | -9.08% | $1.66B | +60.40% | 0.00% |
| MPC | -8.99% | $51.04B | +7.57% | 1.57% |
| KRUS | -8.87% | $1.03B | +38.71% | 0.00% |
| COR | -8.81% | $47.48B | +21.20% | 0.86% |
| WM | -8.80% | $87.92B | +27.58% | 1.34% |
| LRN | -8.80% | $4.43B | +74.97% | 0.00% |
ETF's related to QURE
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 32.68% | $6.58B | 0.35% |
| XPH | 31.99% | $157.87M | 0.35% |
| RSPA | 31.48% | $273.87M | 0% |
| IBB | 30.78% | $6.66B | 0.45% |
| QQA | 30.17% | $135.01M | 0% |
| GNOM | 28.81% | $70.59M | 0.5% |
| FBT | 27.26% | $1.11B | 0.56% |
| PBE | 27.08% | $258.53M | 0.58% |
| BBH | 26.37% | $397.87M | 0.35% |
| PTH | 26.20% | $143.31M | 0.6% |
| IWC | 26.15% | $933.99M | 0.6% |
| IAI | 25.71% | $1.72B | 0.4% |
| KBE | 25.53% | $2.42B | 0.35% |
| FXH | 25.32% | $1.15B | 0.62% |
| KBWB | 25.22% | $2.52B | 0.35% |
| KRE | 25.12% | $4.68B | 0.35% |
| FXO | 25.06% | $1.02B | 0.62% |
| IYF | 25.03% | $3.70B | 0.39% |
| CRUZ | 24.84% | $24.92M | 0.45% |
| KCE | 24.83% | $466.96M | 0.35% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| EPHE | 0.11% | $99.70M | 0.59% |
| XLE | 0.21% | $37.90B | 0.09% |
| IXC | 0.30% | $2.20B | 0.41% |
| PFFR | 0.31% | $112.85M | 0.45% |
| ULST | -0.36% | $535.47M | 0.2% |
| FENY | 0.36% | $1.64B | 0.084% |
| BUXX | 0.43% | $162.67M | 0.25% |
| JUCY | -0.45% | $324.29M | 0.6% |
| FLOT | -0.60% | $7.31B | 0.15% |
| CORN | -0.61% | $61.12M | 0.2% |
| FTXN | 0.72% | $179.41M | 0.6% |
| VRP | 0.75% | $1.83B | 0.5% |
| VDE | 0.78% | $8.33B | 0.1% |
| DUSB | 0.79% | $797.63M | 0.15% |
| XBIL | -0.80% | $637.70M | 0.15% |
| IYK | 0.84% | $1.30B | 0.4% |
| IYE | 0.90% | $1.35B | 0.39% |
| SEIX | 1.04% | $268.81M | 0.62% |
| JPST | 1.23% | $28.43B | 0.18% |
| PBJ | -1.34% | $109.21M | 0.62% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -15.83% | $388.04M | 1.43% |
| KCCA | -11.21% | $220.51M | 0.87% |
| VIXY | -10.81% | $195.31M | 0.85% |
| CLOI | -9.98% | $715.40M | 0.4% |
| UUP | -9.78% | $309.25M | 0.77% |
| COMT | -9.49% | $829.06M | 0.48% |
| DBE | -9.17% | $50.13M | 0.77% |
| CTA | -8.43% | $350.27M | 0.78% |
| DBO | -8.31% | $217.57M | 0.77% |
| SOYB | -8.12% | $27.32M | 0.22% |
| MINT | -8.09% | $11.62B | 0.35% |
| SGOV | -8.07% | $27.53B | 0.09% |
| BCI | -8.01% | $1.20B | 0.26% |
| PDBC | -8.00% | $4.40B | 0.59% |
| FTGC | -7.90% | $2.17B | 1.02% |
| XHLF | -7.82% | $874.27M | 0.03% |
| CMDY | -7.77% | $279.14M | 0.28% |
| USDU | -7.74% | $201.97M | 0.5% |
| DFSD | -7.71% | $3.63B | 0.16% |
| USCI | -7.54% | $185.47M | 1.07% |
News
Yahoo
The average of price targets set by Wall Street analysts indicates a potential upside of 169.2% in uniQure (QURE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Yahoo
Market forces rained on the parade of uniQure N.V. ( NASDAQ:QURE ) shareholders today, when the analysts downgraded...
Yahoo
uniQure ( NASDAQ:QURE ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.29m (up 63% from 3Q 2023). Net...
Yahoo
uniQure (QURE) delivered earnings and revenue surprises of 18.75% and 16.32%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
AMSTERDAM (AP) — UniQure NV (QURE) on Tuesday reported a loss of $44.4 million in its third quarter. The Amsterdam-based company said it had a loss of 91 cents per share. The results topped Wall Street expectations.
Yahoo
~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington’s disease ~ ~ Presented positive interim data from Phase I/II trial of AMT-130 demonstrating slowing of Huntington’s disease progression and reductions in key biomarker of neurodegeneration ~ ~ Initiated patient dosing in new Phase I/II studies of AMT-162 in SOD1-ALS and AMT-191 in Fabry disease; First patient enrolle
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.